| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 175 | 193 | 221 | 210 | 204 | 229 | 269 | 215 | 227 | 257 | 286 | 270 | 276 | 302 | 328 | 305 | 315 | 350 | 380 | 342 | 314 | 277 | 445 | 466 | 445 | 621 | 513 | 509 | 498 | 511 | 543 | 500 | 505 | 555 | 619 | 557 | 564 | 623 | 682 | 622 | 628 | 698 | 755 | 684 |
| Expenses | 128 | 140 | 196 | 119 | 144 | 162 | 182 | 160 | 170 | 184 | 200 | 206 | 203 | 217 | 231 | 227 | 235 | 240 | 257 | 246 | 244 | 218 | 305 | 314 | 309 | 418 | 357 | 388 | 364 | 385 | 390 | 376 | 375 | 395 | 424 | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 507 | 511 |
| EBITDA | 47 | 53 | 25 | 91 | 60 | 67 | 87 | 55 | 57 | 73 | 86 | 64 | 73 | 84 | 98 | 78 | 80 | 110 | 124 | 96 | 69 | 60 | 140 | 152 | 136 | 203 | 156 | 121 | 133 | 126 | 153 | 124 | 130 | 161 | 196 | 159 | 163 | 191 | 224 | 179 | 195 | 220 | 249 | 174 |
| Operating Profit % | 25 % | 26 % | 9 % | 37 % | 27 % | 27 % | 31 % | 23 % | 23 % | 26 % | 28 % | 22 % | 24 % | 26 % | 27 % | 22 % | 22 % | 28 % | 30 % | 25 % | 19 % | 18 % | 29 % | 31 % | 28 % | 31 % | 28 % | 22 % | 25 % | 23 % | 27 % | 23 % | 24 % | 27 % | 30 % | 26 % | 27 % | 28 % | 31 % | 26 % | 28 % | 29 % | 31 % | 23 % |
| Depreciation | 8 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | 8 | 7 | 8 | 8 | 11 | 9 | 9 | 10 | 10 | 16 | 18 | 19 | 20 | 18 | 20 | 20 | 20 | 19 | 21 | 31 | 38 | 36 | 39 | 38 | 38 | 35 | 36 | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 41 | 42 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 9 | 12 | 9 | 11 | 9 | 9 | 8 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 7 |
| Profit Before Tax | 39 | 47 | 18 | 84 | 53 | 61 | 80 | 47 | 49 | 66 | 78 | 56 | 62 | 75 | 88 | 68 | 69 | 89 | 102 | 73 | 45 | 38 | 117 | 129 | 111 | 179 | 131 | 82 | 84 | 81 | 103 | 77 | 83 | 118 | 152 | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 | 124 |
| Tax | 10 | 16 | 11 | 23 | 18 | 21 | 27 | 16 | 17 | 22 | 27 | 19 | 22 | 26 | 31 | 22 | 22 | 30 | 21 | 19 | 13 | 10 | 30 | 33 | 26 | 46 | 34 | 23 | 21 | 23 | 30 | 23 | 26 | 34 | 42 | 34 | 34 | 42 | 52 | 40 | -2 | 47 | 51 | 33 |
| Net Profit | 29 | 31 | 7 | 61 | 35 | 40 | 53 | 31 | 32 | 44 | 51 | 36 | 40 | 50 | 57 | 46 | 47 | 59 | 81 | 55 | 33 | 28 | 87 | 96 | 85 | 134 | 96 | 58 | 62 | 58 | 72 | 54 | 57 | 84 | 111 | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 | 91 |
| EPS in ₹ | 5.28 | 5.61 | 0.99 | 7.37 | 4.17 | 4.88 | 6.47 | 3.78 | 3.80 | 5.40 | 6.19 | 4.39 | 4.88 | 6.00 | 6.92 | 5.56 | 5.72 | 7.14 | 9.77 | 6.56 | 3.94 | 3.45 | 10.34 | 11.44 | 10.10 | 15.87 | 11.49 | 6.93 | 7.41 | 6.97 | 8.64 | 6.37 | 6.84 | 9.95 | 13.16 | 9.77 | 10.13 | 12.79 | 15.52 | 11.60 | 18.57 | 15.88 | 18.05 | 5.42 |
Dr. Lal Path Labs
Dr. Lal Path Labs
1,310.30
-15.10
(-1.14%)
Market Cap
21,954.73 Cr
PE Ratio
41.62
Volume
1,43,922.00
Day High - Low
1,323.40 - 1,291.10
52W High-Low
1,770.00 - 1,175.78
Key Fundamentals
Market Cap
21,954.73 Cr
EPS
58.48
PE Ratio
41.62
PB Ratio
9.29
Book Value
142.51
EBITDA
789.00
Dividend Yield
0.90 %
Industry
Healthcare Services Sector
Healthcare Service Provider Return on Equity
22.31
Debt to Equity
0.10
Analyst Rating and Forecast
- By Refinitiv from23 analysts
Actual
Company News
View All News
Dr. Lal PathLabs schedules board meeting on April 30, 2026 to approve Q4FY26 and FY26 audited financial results. Trading window closed from April 1-May 2, 2026.
CARE Ratings Limited upgraded Dr. Lal PathLabs' issuer rating to CARE AA+ with Stable outlook from CARE AA; Stable, based on the company's operational and financial performance for FY25 and 9MFY26.
CITI Upgrades Dr. Lal PathLabs to Buy, TP Rs 165010 days ago
CITI upgrades Dr. Lal PathLabs to Buy with target price of Rs 1650, citing steady organic growth prospects, strong EBITDA margins, and attractive valuations below historical mean.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,310.30 | #1 21,954.73 | #6 41.62 | #1 2,554.80 | #8 11.28 | #1 492 | #9 -6.83 | 41.75 | |
421.90 | 8,747.16 | 52.76 | 1,346.30 | 10.64 | 146 | 33.65 | 34.47 | |
848.90 | 8,734.90 | 55.99 | 699.70 | 23.06 | 144 | 22.38 | 28.92 | |
348.75 | 5,550.89 | 42.25 | 702.20 | 20.80 | 91 | 47.37 | 41.00 | |
505.15 | 5,068.71 | 73.62 | 769.90 | 33.97 | 67 | 60.20 | 45.40 | |
529.25 | 1,716.82 | 22.15 | 742.70 | 16.70 | 78 | -21.13 | 26.68 | |
228.45 | 1,189.78 | 37.49 | 255.90 | 15.11 | 31 | 20.00 | 30.17 | |
1,155.00 | 991.33 | 17.23 | 111.60 | 28.72 | 48 | 65.93 | 34.53 | |
478.95 | 936.06 | #1 16.10 | 147.80 | #1 134.60 | 19 | #1 520.00 | 36.66 | |
275.00 | 874.79 | 29.96 | 1,170.80 | -18.47 | -134 | 101.06 | 43.37 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
11.28 %
Net Income Growth
35.88 %
Cash Flow Change
6.27 %
ROE
16.08 %
ROCE
4.10 %
EBITDA Margin (Avg.)
4.50 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 475 | 625 | 764 | 916 | 1,091 | 1,374 | 1,661 | 2,353 | 2,386 | 2,456 | 2,717 |
| Fixed Assets | 150 | 166 | 190 | 208 | 209 | 413 | 447 | 1,375 | 1,305 | 1,228 | 1,168 |
| Current Assets | 282 | 424 | 511 | 623 | 814 | 893 | 1,145 | 875 | 973 | 1,127 | 1,364 |
| Capital Work in Progress | 1 | 4 | 18 | 10 | 3 | 11 | 10 | 15 | 5 | 6 | 4 |
| Investments | 38 | 64 | 105 | 145 | 185 | 164 | 59 | 66 | 150 | 114 | 327 |
| Other Assets | 286 | 391 | 452 | 554 | 694 | 786 | 1,145 | 898 | 926 | 1,109 | 1,218 |
| Total Equity & Liabilities | 475 | 625 | 764 | 916 | 1,091 | 1,374 | 1,661 | 2,353 | 2,386 | 2,456 | 2,717 |
| Current Liabilities | 112 | 91 | 74 | 116 | 138 | 227 | 274 | 500 | 470 | 465 | 402 |
| Non Current Liabilities | 20 | 24 | 28 | 8 | 1 | 93 | 111 | 310 | 216 | 105 | 108 |
| Total Equity | 343 | 510 | 662 | 792 | 951 | 1,054 | 1,276 | 1,544 | 1,700 | 1,885 | 2,207 |
| Reserve & Surplus | 260 | 424 | 577 | 734 | 890 | 974 | 1,162 | 1,425 | 1,583 | 1,766 | 2,089 |
| Share Capital | 81 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 84 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 8 | -5 | 2 | 37 | 64 | 67 | 48 | 134 | -115 | 97 | -68 |
| Investing Activities | -114 | -164 | -137 | -172 | -100 | -26 | -212 | -449 | -287 | -24 | -303 |
| Operating Activities | 122 | 159 | 171 | 197 | 219 | 284 | 398 | 447 | 456 | 535 | 569 |
| Financing Activities | -1 | 0 | -32 | 13 | -55 | -190 | -139 | 136 | -283 | -414 | -334 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 55.23 % | 55.23 % | 55.23 % | 55.23 % | 55.23 % | 55.05 % | 55.05 % | 55.05 % | 55.03 % | 55.01 % | 54.61 % | 54.60 % | 54.60 % | 54.60 % | 53.92 % | 53.91 % | 53.91 % | 53.79 % | 53.21 % | 53.21 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.00 % | 1.83 % | 0.00 % | 0.00 % | 0.00 % | 26.15 % | 25.42 % | 26.82 % | 26.82 % | 23.91 % | 21.68 % | 21.86 % | 20.29 % |
| DIIs | 6.47 % | 5.61 % | 4.84 % | 5.58 % | 5.69 % | 5.30 % | 5.09 % | 6.19 % | 6.55 % | 7.33 % | 7.97 % | 8.61 % | 9.69 % | 12.71 % | 12.89 % | 13.17 % | 16.08 % | 17.91 % | 18.49 % | 19.21 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % |
| Public / Retail | 5.70 % | 6.24 % | 6.93 % | 7.45 % | 9.03 % | 10.44 % | 8.24 % | 9.03 % | 9.50 % | 9.31 % | 8.37 % | 7.26 % | 6.47 % | 4.91 % | 4.10 % | 4.01 % | 4.11 % | 5.23 % | 5.19 % | 5.82 % |
| Others | 32.60 % | 32.92 % | 32.99 % | 31.74 % | 30.05 % | 29.22 % | 31.63 % | 27.73 % | 27.09 % | 28.35 % | 29.05 % | 29.53 % | 3.09 % | 2.35 % | 2.27 % | 2.10 % | 2.00 % | 1.38 % | 1.25 % | 1.47 % |
| No of Share Holders | 68,845 | 94,123 | 1,25,953 | 1,35,068 | 1,71,846 | 1,84,508 | 1,71,602 | 1,79,636 | 1,80,163 | 1,74,444 | 1,60,679 | 1,49,901 | 1,46,741 | 1,31,189 | 1,16,606 | 1,16,236 | 1,15,699 | 1,18,656 | 1,12,703 | 1,14,385 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3 | 4.5 | 6 | 12 | 20 | 12 | 12 | 24 | 24 | 0.00 |
| Dividend Yield (%) | 0.68 | 0.86 | 0.86 | 0.89 | 1.53 | 1.31 | 1.06 | 1.94 | 1.81 | 0.00 |
Announcements
Closure of Trading Window
2 days ago
2 days agoBoard Meeting Intimation for Notice Of Board Meeting2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Credit Rating4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 12, 2026
Mar 12, 2026Update On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited (A Wholly Owned Subsidiary Of The Company)-Receipt Of NCLT OrderMar 10, 2026
Mar 10, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2026
Jan 31, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2026
Jan 30, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJan 30, 2026
Jan 30, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2026
Jan 30, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 30, 2026
Jan 30, 2026Fixes Record Date For 3Rd Interim Dividend FY 2025-26Jan 30, 2026
Jan 30, 2026Corporate Action-Board approves DividendJan 30, 2026
Jan 30, 2026Board Meeting Outcome for Outcome Of Board Meeting Dated January 30 2026Jan 30, 2026
Jan 30, 2026Financial Results For The Quarter And Nine Months Ended December 31 2025Jan 30, 2026
Jan 30, 2026Financial Results For The Quarter And Nine Months Ended December 31 2025Jan 30, 2026
Jan 30, 2026Update on board meetingJan 23, 2026
Jan 23, 2026Corporate Action-Board to consider DividendJan 23, 2026
Jan 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2026
Jan 08, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2026
Jan 07, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 06, 2026
Jan 06, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Board Meeting Intimation for Notice Of Board MeetingDec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-AllotmentDec 22, 2025
Dec 22, 2025Amended Trust Deed (ESOP)Dec 15, 2025
Dec 15, 2025Intimation Of Record Date For The Purpose Of Issuing Bonus Equity SharesDec 12, 2025
Dec 12, 2025Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationDec 08, 2025
Dec 08, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportDec 08, 2025
Dec 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 26, 2025
Nov 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2025
Nov 08, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 01, 2025
Nov 01, 2025Receipt Of An Assessment Order And Demand Notice Issued By Income Tax DepartmentNov 01, 2025
Nov 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationOct 31, 2025
Oct 31, 2025Record Date For 2Nd Interim Dividend FY 2025-26Oct 31, 2025
Oct 31, 2025Introduction Of Dr. Lal Pathlabs Employee RSU 2025 (ESOP Scheme)Oct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesOct 31, 2025
Oct 31, 2025Corporate Action-Board recommends Bonus IssueOct 31, 2025
Oct 31, 2025Financial Results For The Quarter And Half Year Ended September 30 2025Oct 31, 2025
Oct 31, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On October 31 2025Oct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 27, 2025
Oct 27, 2025Board Meeting Intimation for Notice Of Board MeetingOct 24, 2025
Oct 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 41.75
ATR(14)
Volatile 42.61
STOCH(9,6)
Neutral 33.76
STOCH RSI(14)
Neutral 39.72
MACD(12,26)
Bearish -1.41
ADX(14)
Weak Trend 17.21
UO(9)
Bearish 49.93
ROC(12)
Downtrend And Accelerating -3.83
WillR(14)
Neutral -62.90
About Dr. Lal Path Labs
Dr Lal PathLabs is a leading diagnostic healthcare service provider in India. The company operates a nationwide network of medical laboratory centers, offering over 5000 diagnostic tests and related healthcare services. Its infrastructure includes a National Reference Laboratory in New Delhi, Regional Reference Labs in Kolkata, Bangalore, and Mumbai, 371...more
Listing Date
23 Dec, 2015(10 Years,
35 days)
Website
Chairperson NameArvind Lal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
